{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:09:30Z","timestamp":1789747770638,"version":"4.0.1"},"reference-count":246,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001171","name":"Cancer Institute New South Wales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.addr.2018.08.012","type":"journal-article","created":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T11:51:03Z","timestamp":1536061863000},"page":"107-130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"special_numbering":"C","title":["The potential to treat lung cancer via inhalation of repurposed drugs"],"prefix":"10.1016","volume":"133","author":[{"given":"Wing-Hin","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Yee","family":"Loo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maliheh","family":"Ghadiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chean-Ring","family":"Leong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Traini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2018.08.012_bb0005","unstructured":"Key statistics for Lung Cancer http:\/\/www.cancer.org\/cancer\/lungcancer-non-smallcell\/detailedguide\/non-small-cell-lung-cancer-key-statistics#, 2016 (updated 05\/16\/2016)."},{"key":"10.1016\/j.addr.2018.08.012_bb0010","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/JTO.0b013e31818020eb","article-title":"The international epidemiology of lung cancer: geographical distribution and secular trends","volume":"3","author":"Youlden","year":"2008","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.addr.2018.08.012_bb0015","first-page":"189","article-title":"Lung cancer: biology and treatment options","volume":"1856","author":"Lemjabbar-Alaoui","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.addr.2018.08.012_bb0020","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jconrel.2017.05.023","article-title":"Advances in combination therapy of lung cancer: rationales, delivery technologies and dosage regimens","volume":"260","author":"Wu","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2018.08.012_bb0025","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.biopha.2017.03.018","article-title":"Current FDA-approved treatments for non-small cell lung cancer and potential biomarkers for its detection","volume":"90","author":"Ruiz-Ceja","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.addr.2018.08.012_bb0030","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ctrv.2010.12.007","article-title":"Maintenance chemotherapy for non-small-cell lung cancer","volume":"37","author":"Kim","year":"2011","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.addr.2018.08.012_bb0035","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel\u2013carboplatin alone or with bevacizumab for non\u2013small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2018.08.012_bb0040","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2018.08.012_bb0045","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2018.08.012_bb0050","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s40265-016-0578-z","article-title":"Management of NSCLC disease progression after first-line EGFR tyrosine kinase inhibitors: what are the issues and potential therapies?","volume":"76","author":"Califano","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2018.08.012_bb0055","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S1470-2045(11)70385-0","article-title":"Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study","volume":"13","author":"Ciuleanu","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.addr.2018.08.012_bb0060","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2217\/fon.14.244","article-title":"Repurposing drugs in your medicine cabinet: untapped opportunities for cancer therapy?","volume":"11","author":"Pantziarka","year":"2015","journal-title":"Future Oncol."},{"key":"10.1016\/j.addr.2018.08.012_bb0065","doi-asserted-by":"crossref","first-page":"5972","DOI":"10.1158\/1078-0432.CCR-10-1277","article-title":"Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much?","volume":"16","author":"Fojo","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2018.08.012_bb0070","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nbt.2786","article-title":"Clinical development success rates for investigational drugs","volume":"32","author":"Hay","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2018.08.012_bb0075","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd3078","article-title":"How to improve R&D productivity: the pharmaceutical industry's grand challenge","volume":"9","author":"Paul","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2018.08.012_bb0080","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2018.08.012_bb0085","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.drudis.2015.05.001","article-title":"Drug repositioning and repurposing: terminology and definitions in literature","volume":"20","author":"Langedijk","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.addr.2018.08.012_bb0090","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3332\/ecancer.2014.485","article-title":"The repurposing drugs in oncology (ReDO) project","volume":"8","author":"Pantziarka","year":"2014","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.addr.2018.08.012_bb0095","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jconrel.2004.11.009","article-title":"Preparation of in vivo cleavable agglomerated liposomes suitable for modulated pulmonary drug delivery","volume":"103","author":"Karathanasis","year":"2005","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2018.08.012_bb0100","first-page":"123","article-title":"Formulation technology to repurpose drugs for inhalation delivery","volume":"8","author":"Cipolla","year":"2011","journal-title":"Drug Disc. Today: Therapeut. Strat."},{"key":"10.1016\/j.addr.2018.08.012_bb0105","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1089\/jamp.2011-0966","article-title":"Characterization and application of a nose-only exposure chamber for inhalation delivery of liposomal drugs and nucleic acids to mice","volume":"26","author":"Mainelis","year":"2013","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2018.08.012_bb0110","doi-asserted-by":"crossref","first-page":"914","DOI":"10.3109\/1061186X.2013.829078","article-title":"Nanotechnology approaches for inhalation treatment of fibrosis","volume":"21","author":"Savla","year":"2013","journal-title":"J. Drug Target."},{"key":"10.1016\/j.addr.2018.08.012_bb0115","first-page":"44","article-title":"Inhalation treatment of lung cancer: the influence of composition, size and shape of nanocarriers on their lung accumulation and retention","volume":"11","author":"Garbuzenko","year":"2014","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.addr.2018.08.012_bb0120","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s11095-008-9755-4","article-title":"Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug","volume":"26","author":"Garbuzenko","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2018.08.012_bb0125","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jconrel.2015.07.024","article-title":"Nanotechnology approaches for inhalation treatment of lung diseases","volume":"219","author":"Kuzmov","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2018.08.012_bb0130","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2174\/1874306401206010063","article-title":"Drug induced interstitial lung disease","volume":"6","author":"Schwaiblmair","year":"2012","journal-title":"Open Respir. Med. J."},{"key":"10.1016\/j.addr.2018.08.012_bb0135","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/aps.2017.34","article-title":"Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities","volume":"38","author":"Mangal","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.addr.2018.08.012_bb0140","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.2147\/IJN.S29997","article-title":"Inhaled chemotherapy in lung cancer: future concept of nanomedicine","volume":"7","author":"Zarogoulidis","year":"2012","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2018.08.012_bb0145","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nrc1893","article-title":"Drug penetration in solid tumours","volume":"6","author":"Minchinton","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.addr.2018.08.012_bb0150","first-page":"1583","article-title":"Penetration of anticancer drugs through solid tissue: a factor that limits the effectiveness of chemotherapy for solid tumors","volume":"5","author":"Tunggal","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2018.08.012_bb0155","first-page":"2653","article-title":"Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: proof of principle using dogs with spontaneously occurring tumors as a model","volume":"5","author":"Hershey","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2018.08.012_bb0160","first-page":"837","article-title":"Clinical observations of aerosol deposition in patients with airways obstruction","volume":"80","author":"Itoh","year":"1981","journal-title":"Chest"},{"key":"10.1016\/j.addr.2018.08.012_bb0165","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1080\/08958370290084809","article-title":"Aerosol transport and deposition in a triple bifurcation bronchial airway model with local tumors","volume":"14","author":"Zhang","year":"2002","journal-title":"Inhal. Toxicol."},{"key":"10.1016\/j.addr.2018.08.012_bb0170","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1089\/jamp.2007.0656","article-title":"Aerosolized chemotherapy","volume":"21","author":"Gagnadoux","year":"2008","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2018.08.012_bb0175","first-page":"481","article-title":"Inhalation of nanoparticle-based drug for lung cancer treatment: advantages and challenges","volume":"10","author":"Lee","year":"2015","journal-title":"Asian J. Pharmaceut. Sci."},{"key":"10.1016\/j.addr.2018.08.012_bb0180","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S2213-2600(13)70072-9","article-title":"Pulmonary drug delivery: from generating aerosols to overcoming biological barriers-therapeutic possibilities and technological challenges","volume":"1","author":"Ruge","year":"2013","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.addr.2018.08.012_bb0185","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1634\/theoncologist.2015-0064","article-title":"Therapeutic effects of repurposed therapies in non-small cell lung cancer: what is old is new again","volume":"20","author":"Saxena","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.addr.2018.08.012_bb0190","doi-asserted-by":"crossref","first-page":"13371","DOI":"10.1073\/pnas.222543099","article-title":"Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum?","volume":"99","author":"Warner","year":"2002","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.addr.2018.08.012_bb0195","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0140-6736(99)12031-2","article-title":"COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease","volume":"355","author":"Willoughby","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2018.08.012_bb0200","first-page":"419","article-title":"Role of cyclooxygenase-2 in tumor progression and immune regulation in lung cancer","volume":"44","author":"Patel","year":"2007","journal-title":"Indian J. Biochem. Biophys."},{"key":"10.1016\/j.addr.2018.08.012_bb0205","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s13193-014-0290-y","article-title":"Role of cyclooxygenase 2 (COX-2) in prognosis of breast cancer","volume":"5","author":"Jana","year":"2014","journal-title":"Indian J. Surg. Oncol."},{"key":"10.1016\/j.addr.2018.08.012_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/mc.20449","article-title":"Overexpression of cyclooxygenase-2 (COX-2) in the mouse urinary bladder induces the expression of immune- and cell proliferation-related genes","volume":"48","author":"Wang","year":"2009","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.addr.2018.08.012_bb0215","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/(SICI)1097-0045(20000101)42:1<73::AID-PROS9>3.0.CO;2-G","article-title":"Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma","volume":"42","author":"Gupta","year":"2000","journal-title":"Prostate"},{"key":"10.1016\/j.addr.2018.08.012_bb0220","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/00000658-200203000-00017","article-title":"Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer","volume":"235","author":"Brabender","year":"2002","journal-title":"Ann. Surg."},{"key":"10.1016\/j.addr.2018.08.012_bb0225","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1136\/gut.50.6.857","article-title":"A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis","volume":"50","author":"Phillips","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.addr.2018.08.012_bb0230","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJM200006293422603","article-title":"The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis","volume":"342","author":"Steinbach","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2018.08.012_bb0235","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/ajg.2009.758","article-title":"The safety and efficacy of celecoxib in children with familial adenomatous polyposis","volume":"105","author":"Lynch","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.addr.2018.08.012_bb0240","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/gutjnl-2014-307235","article-title":"An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis","volume":"65","author":"Lynch","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.addr.2018.08.012_bb0245","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejphar.2015.11.007","article-title":"Cyclooxygenase-2 inhibitors in lung cancer treatment: bench to bed","volume":"769","author":"Liu","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.addr.2018.08.012_bb0250","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1734-1140(10)70262-0","article-title":"COX-2 as a target for cancer chemotherapy","volume":"62","author":"Ghosh","year":"2010","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.addr.2018.08.012_bb0255","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.canlet.2004.11.002","article-title":"Anti-proliferative and apoptotic effects of celecoxib on human chronic myeloid leukemia in vitro","volume":"224","author":"Subhashini","year":"2005","journal-title":"Cancer Lett."},{"key":"10.1016\/j.addr.2018.08.012_bb0260","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.bcp.2008.06.015","article-title":"Celecoxib potently inhibits TNFalpha-induced nuclear translocation and activation of NF-kappaB","volume":"76","author":"Funakoshi-Tago","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.addr.2018.08.012_bb0265","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.bbrc.2017.06.148","article-title":"Celecoxib induced apoptosis against different breast cancer cell lines by down-regulated NF-kappaB pathway","volume":"490","author":"Wang","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.addr.2018.08.012_bb0270","doi-asserted-by":"crossref","first-page":"11397","DOI":"10.1074\/jbc.275.15.11397","article-title":"The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2","volume":"275","author":"Hsu","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.addr.2018.08.012_bb0275","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-016-0378-2","article-title":"Celecoxib enhances anticancer effect of cisplatin and induces anoikis in osteosarcoma via PI3K\/Akt pathway","volume":"17","author":"Liu","year":"2017","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.addr.2018.08.012_bb0280","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3892\/ijmm.2014.1713","article-title":"Celecoxib regulates apoptosis and autophagy via the PI3K\/Akt signaling pathway in SGC-7901 gastric cancer cells","volume":"33","author":"Liu","year":"2014","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.addr.2018.08.012_bb0285","doi-asserted-by":"crossref","first-page":"27613","DOI":"10.1074\/jbc.M201119200","article-title":"Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line","volume":"277","author":"Arico","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2018.08.012_bb0290","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s11095-004-1881-z","article-title":"Formulation and evaluation of aerosolized celecoxib for the treatment of lung cancer","volume":"22","author":"Haynes","year":"2005","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2018.08.012_bb0295","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1211\/jpp.58.3.0006","article-title":"Anti-cancer effect of celecoxib and aerosolized docetaxel against human non-small cell lung cancer cell line, A549","volume":"58","author":"Fulzele","year":"2006","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.addr.2018.08.012_bb0300","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1007\/s11095-006-9074-6","article-title":"Inhalation delivery and anti-tumor activity of celecoxib in human orthotopic non-small cell lung cancer xenograft model","volume":"23","author":"Fulzele","year":"2006","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2018.08.012_bb0305","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jconrel.2010.02.006","article-title":"Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers","volume":"144","author":"Patlolla","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2018.08.012_bb0310","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s11095-013-0984-9","article-title":"Efficacy of aerosolized celecoxib encapsulated nanostructured lipid carrier in non-small cell lung cancer in combination with docetaxel","volume":"30","author":"Patel","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2018.08.012_bb0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2016.03.025","article-title":"Nebulizable colloidal nanoparticles co-encapsulating a COX-2 inhibitor and a herbal compound for treatment of lung cancer","volume":"103","author":"Said-Elbahr","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2018.08.012_bb0320","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1023\/A:1025774630993","article-title":"Evaluation of an aerosolized selective COX-2 inhibitor as a potentiator of doxorubicin in a non-small-cell lung cancer cell line","volume":"20","author":"Haynes","year":"2003","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2018.08.012_bb0325","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1158\/1535-7163.MCT-13-0006-T","article-title":"Aerosol administration of phospho-sulindac inhibits lung tumorigenesis","volume":"12","author":"Cheng","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.addr.2018.08.012_bb0330","doi-asserted-by":"crossref","first-page":"7746","DOI":"10.1038\/sj.onc.1207985","article-title":"Budesonide exerts its chemopreventive efficacy during mouse lung tumorigenesis by modulating gene expressions","volume":"23","author":"Yao","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.addr.2018.08.012_bb0335","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/carcin\/21.2.179","article-title":"Chemoprevention of pulmonary carcinogenesis by brief exposures to aerosolized budesonide or beclomethasone dipropionate and by the combination of aerosolized budesonide and dietary myo-inositol","volume":"21","author":"Wattenberg","year":"2000","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.addr.2018.08.012_bb0340","first-page":"5489","article-title":"Chemoprevention of pulmonary carcinogenesis by aerosolized budesonide in female A\/J mice","volume":"57","author":"Wattenberg","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2018.08.012_bb0345","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1158\/1940-6207.CAPR-09-0221","article-title":"Preventive effects of bexarotene and budesonide in a genetically engineered mouse model of small cell lung cancer","volume":"2","author":"Wang","year":"2009","journal-title":"Cancer Prev. Res. (Phila.)"},{"key":"10.1016\/j.addr.2018.08.012_bb0350","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1002\/ijc.24942","article-title":"Prevention of cigarette smoke-induced lung tumors in mice by budesonide, phenethyl isothiocyanate, and N-acetylcysteine","volume":"126","author":"Balansky","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.addr.2018.08.012_bb0355","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/mc.20751","article-title":"Chemoprevention of lung carcinogenesis by the combination of aerosolized budesonide and oral pioglitazone in A\/J mice","volume":"50","author":"Fu","year":"2011","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.addr.2018.08.012_bb0360","unstructured":"J. Zhang, Chemoprevention of Lung Carcinogenesis: Aerosol Administration and Deposition in the Mouse Lung. All Theses and Dissertations (ETDs). School of Engineering & Applied Science, Washington University, St. Louis, 2013."},{"key":"10.1016\/j.addr.2018.08.012_bb0365","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.1158\/1538-7445.AM2017-5267","article-title":"Abstract 5267: chemoprevention of lung carcinogenesis by dietary nicotinamide and inhaled budesonide","volume":"77","author":"Seabloom","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2018.08.012_bb0370","doi-asserted-by":"crossref","first-page":"6502","DOI":"10.1158\/1078-0432.CCR-04-0686","article-title":"A randomized phase IIb trial of pulmicort turbuhaler (budesonide) in people with dysplasia of the bronchial epithelium","volume":"10","author":"Lam","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2018.08.012_bb0375","doi-asserted-by":"crossref","first-page":"4266s","DOI":"10.1158\/1078-0432.CCR-040014","article-title":"Cyclooxygenase as a target in lung cancer","volume":"10","author":"Brown","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2018.08.012_bb0380","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1164\/rccm.200608-1125OC","article-title":"Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease","volume":"175","author":"Parimon","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2018.08.012_bb0385","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.rmed.2008.07.024","article-title":"Inhaled corticosteroids and risk of lung cancer among COPD patients who quit smoking","volume":"103","author":"Kiri","year":"2009","journal-title":"Respir. Med."},{"key":"10.1016\/j.addr.2018.08.012_bb0390","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.rmed.2012.12.002","article-title":"Inhaled corticosteroid use and risks of lung cancer and laryngeal cancer","volume":"107","author":"Lee","year":"2013","journal-title":"Respir. Med."},{"key":"10.1016\/j.addr.2018.08.012_bb0395","doi-asserted-by":"crossref","first-page":"29711","DOI":"10.18632\/oncotarget.15386","article-title":"Inhaled corticosteroids have a protective effect against lung cancer in female patients with chronic obstructive pulmonary disease: a nationwide population-based cohort study","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.addr.2018.08.012_bb0400","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1200\/JCO.1994.12.5.937","article-title":"Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia","volume":"12","author":"Lee","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2018.08.012_bb0405","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.cct.2010.08.006","article-title":"Budesonide versus placebo in high-risk population with screen-detected lung nodules: rationale, design and methodology","volume":"31","author":"Lazzeroni","year":"2010","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.addr.2018.08.012_bb0410","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/1940-6207.CAPR-10-0182","article-title":"Randomized phase II trial of inhaled budesonide versus placebo in high-risk individuals with CT screen-detected lung nodules","volume":"4","author":"Veronesi","year":"2011","journal-title":"Cancer Prev. Res. (Phila.)"},{"key":"10.1016\/j.addr.2018.08.012_bb0415","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/annonc\/mdv064","article-title":"Long-term effects of inhaled budesonide on screening-detected lung nodules","volume":"26","author":"Veronesi","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.addr.2018.08.012_bb0420","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1158\/1940-6207.CAPR-16-0174","article-title":"Safety and preclinical efficacy of aerosol pioglitazone on lung adenoma prevention in A\/J mice","volume":"10","author":"Seabloom","year":"2017","journal-title":"Cancer Prev. Res. (Phila.)"},{"key":"10.1016\/j.addr.2018.08.012_bb0425","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.ijcard.2014.11.031","article-title":"A review of clinical studies on angiotensin II receptor blockers and risk of cancer","volume":"177","author":"Dezsi","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.addr.2018.08.012_bb0430","doi-asserted-by":"crossref","first-page":"735","DOI":"10.7326\/0003-4819-157-10-201211200-00011","volume":"157","author":"Qaseem","year":"2012","journal-title":"Ann. Intern. Med."},{"issue":"2013","key":"10.1016\/j.addr.2018.08.012_bb0435","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1161\/CIR.0b013e3182742c84","article-title":"ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"127","author":"O'Gara","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2018.08.012_bb0440","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1080\/03639045.2016.1190741","article-title":"Sigma-2 receptor ligand anchored telmisartan loaded nanostructured lipid particles augmented drug delivery, cytotoxicity, apoptosis and cellular uptake in prostate cancer cells","volume":"42","author":"Puri","year":"2016","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.addr.2018.08.012_bb0445","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.3892\/ol.2014.2592","article-title":"Antiproliferative and apoptotic effects of telmisartan in human colon cancer cells","volume":"8","author":"Lee","year":"2014","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.addr.2018.08.012_bb0450","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejphar.2016.02.017","article-title":"Increase of human prostate cancer cell (DU145) apoptosis by telmisartan through PPAR-delta pathway","volume":"775","author":"Wu","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.addr.2018.08.012_bb0455","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/1535370214546267","article-title":"Telmisartan induces apoptosis and regulates Bcl-2 in human renal cancer cells","volume":"240","author":"de Araujo Junior","year":"2015","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"10.1016\/j.addr.2018.08.012_bb0460","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.msec.2016.11.048","article-title":"Soluble telmisartan bearing poly (ethylene glycol) conjugated chitosan nanoparticles augmented drug delivery, cytotoxicity, apoptosis and cellular uptake in human cervical cancer cells","volume":"72","author":"Sharma","year":"2017","journal-title":"Mater. Sci. Eng. C Mater. Biol. Appl."},{"key":"10.1016\/j.addr.2018.08.012_bb0465","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jconrel.2013.06.036","article-title":"Inhalation delivery of Telmisartan enhances intratumoral distribution of nanoparticles in lung cancer models","volume":"172","author":"Godugu","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2018.08.012_bb0470","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s00423-002-0314-x","article-title":"Wortmannin inhibits growth of human non-small-cell lung cancer in vitro and in vivo","volume":"387","author":"Boehle","year":"2002","journal-title":"Langenbeck's Arch. Surg."},{"key":"10.1016\/j.addr.2018.08.012_bb0475","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/ijc.21927","article-title":"Inhibitors of the PI3-kinase\/Akt pathway induce mitotic catastrophe in non-small cell lung cancer cells","volume":"119","author":"Hemstrom","year":"2006","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.addr.2018.08.012_bb0480","first-page":"1683","article-title":"Inhibition of PI3 kinases enhances the sensitivity of non-small cell lung cancer cells to ionizing radiation","volume":"24","author":"Zhang","year":"2010","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.addr.2018.08.012_bb0485","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1158\/1535-7163.763.3.7","article-title":"Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling","volume":"3","author":"Ihle","year":"2004","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.addr.2018.08.012_bb0490","first-page":"1098","article-title":"Pharmacokinetic and pharmacodynamic studies of a novel antitumor wortmannin analogue inhibitor of phosphatidylinositol-3-kinase","volume":"64","author":"Powis","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2018.08.012_bb0495","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1021\/jm050901o","article-title":"Pegylated wortmannin and 17-hydroxywortmannin conjugates as phosphoinositide 3-kinase inhibitors active in human tumor xenograft models","volume":"49","author":"Zhu","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2018.08.012_bb0500","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1021\/jm901427g","article-title":"Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel wortmannin-rapamycin conjugates","volume":"53","author":"Ayral-Kaloustian","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2018.08.012_bb0505","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4161\/cbt.4.5.1660","article-title":"PWT-458, a novel pegylated-17-hydroxywortmannin, inhibits phosphatidylinositol 3-kinase signaling and suppresses growth of solid tumors","volume":"4","author":"Yu","year":"2005","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.addr.2018.08.012_bb0510","doi-asserted-by":"crossref","first-page":"8230","DOI":"10.1073\/pnas.1120508109","article-title":"Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery","volume":"109","author":"Karve","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2018.08.012_bb0515","doi-asserted-by":"crossref","first-page":"8976","DOI":"10.1021\/acsnano.5b02913","article-title":"Improving cancer chemoradiotherapy treatment by dual controlled release of wortmannin and docetaxel in polymeric nanoparticles","volume":"9","author":"Au","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2018.08.012_bb0520","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/med.21357","article-title":"The noscapine chronicle: a pharmaco-historic biography of the opiate alkaloid family and its clinical applications","volume":"35","author":"Rida","year":"2015","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.addr.2018.08.012_bb0525","doi-asserted-by":"crossref","first-page":"726","DOI":"10.4149\/neo_2016_509","article-title":"Noscapine inhibits human hepatocellular carcinoma growth through inducing apoptosis in vitro and in vivo","volume":"63","author":"Xu","year":"2016","journal-title":"Neoplasma"},{"key":"10.1016\/j.addr.2018.08.012_bb0530","doi-asserted-by":"crossref","DOI":"10.1038\/srep37062","article-title":"Noscapine targets EGFR(p-Tyr1068) to suppress the proliferation and invasion of MG63 cells","volume":"6","author":"He","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2018.08.012_bb0535","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146804","article-title":"Formulation, pharmacokinetic, and efficacy studies of mannosylated self-emulsifying solid dispersions of noscapine","volume":"11","author":"Andey","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2018.08.012_bb0540","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1158\/0008-5472.CAN-06-4282","article-title":"p53 and p21 determine the sensitivity of noscapine-induced apoptosis in colon cancer cells","volume":"67","author":"Aneja","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2018.08.012_bb0545","article-title":"Noscapine induced apoptosis via downregulation of survivin in human neuroblastoma cells having wild type or null p53","volume":"7","author":"Li","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2018.08.012_bb0550","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1002\/slct.201600959","article-title":"Subtle alterations in microtubule assembly dynamics by Br-TMB-Noscapine Strongly suppress triple-negative breast cancer cell viability without mitotic arrest","volume":"1","author":"Mahaddalkar","year":"2016","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.addr.2018.08.012_bb0555","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jcis.2014.12.092","article-title":"Inhalable nanostructured lipid particles of 9-bromo-noscapine, a tubulin-binding cytotoxic agent: in vitro and in vivo studies","volume":"445","author":"Jyoti","year":"2015","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.addr.2018.08.012_bb0560","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1089\/089426802760292609","article-title":"Inhalation delivery of anticancer agents via HFA-based metered dose inhaler using methotrexate as a model drug","volume":"15","author":"Shaik","year":"2002","journal-title":"J. Aerosol. Med."},{"key":"10.1016\/j.addr.2018.08.012_bb0565","first-page":"395","article-title":"Cyclosporin A aerosol improves the anticancer effect of paclitaxel aerosol in mice","volume":"115","author":"Knight","year":"2004","journal-title":"Trans. Am. Clin. Climatol. Assoc."},{"key":"10.1016\/j.addr.2018.08.012_bb0570","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1089\/089426804322994415","article-title":"Cyclosporin A aerosol improves the anticancer effect of paclitaxel aerosol in mice","volume":"17","author":"Koshkina","year":"2004","journal-title":"J. Aerosol Med."},{"key":"10.1016\/j.addr.2018.08.012_bb0575","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S0190-9622(98)70438-4","article-title":"Pharmacokinetics of oral isotretinoin","volume":"39","author":"Wiegand","year":"1998","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.addr.2018.08.012_bb0580","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1080\/01635588109513704","article-title":"13-cis retinoic acid and murine pulmonary adenomas: a preliminary report","volume":"3","author":"Frasca","year":"1981","journal-title":"Nutr. Cancer"},{"key":"10.1016\/j.addr.2018.08.012_bb0585","first-page":"3015","article-title":"Inhaled isotretinoin (13-cis retinoic acid) is an effective lung cancer chemopreventive agent in A\/J mice at low doses: a pilot study","volume":"6","author":"Dahl","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2018.08.012_bb0590","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3109\/01902141003790155","article-title":"Uptake of all-trans retinoic acid-containing aerosol by inhalation to lungs in a guinea pig model system--a pilot study","volume":"36","author":"Schaffer","year":"2010","journal-title":"Exp. Lung Res."},{"key":"10.1016\/j.addr.2018.08.012_bb0595","first-page":"95","article-title":"Farnesol for aerosol inhalation: nebulization and activity against human lung cancer cells","volume":"6","author":"Wang","year":"2003","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.addr.2018.08.012_bb0600","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1158\/1940-6207.CAPR-10-0117","article-title":"Chemopreventive efficacy and mechanism of licofelone in a mouse lung tumor model via aspiration","volume":"4","author":"Sharma","year":"2011","journal-title":"Cancer Prev. Res. (Phila.)"},{"key":"10.1016\/j.addr.2018.08.012_bb0605","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1158\/1940-6207.CAPR-10-0246","article-title":"Aerosolized bexarotene inhibits lung tumorigenesis without increasing plasma triglyceride and cholesterol levels in mice","volume":"4","author":"Zhang","year":"2011","journal-title":"Cancer Prev. Res. (Phila.)"},{"key":"10.1016\/j.addr.2018.08.012_bb0610","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1166\/jbn.2016.2162","article-title":"Synthesis and characterization of inhalable flavonoid nanoparticle for lung cancer cell targeting","volume":"12","author":"Lee","year":"2016","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.addr.2018.08.012_bb0615","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1593\/neo.07160","article-title":"Chemopreventive effect of aerosolized polyphenon E on lung tumorigenesis in A\/J mice","volume":"9","author":"Yan","year":"2007","journal-title":"Neoplasia"},{"key":"10.1016\/j.addr.2018.08.012_bb0620","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/1535-7163.MCT-09-1104","article-title":"Inhalation delivery of a novel diindolylmethane derivative for the treatment of lung cancer","volume":"9","author":"Ichite","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.addr.2018.08.012_bb0625","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/COC.0b013e318173a536","article-title":"A dose-escalation study of aerosolized sargramostim in the treatment of metastatic melanoma: an NCCTG Study","volume":"31","author":"Markovic","year":"2008","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.addr.2018.08.012_bb0630","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3332\/ecancer.2015.521","article-title":"Repurposing Drugs in Oncology (ReDO)-itraconazole as an anti-cancer agent","volume":"9","author":"Pantziarka","year":"2015","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.addr.2018.08.012_bb0635","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1021\/acs.jmedchem.5b01718","article-title":"Repurposing the clinically efficacious antifungal agent itraconazole as an anticancer chemotherapeutic","volume":"59","author":"Pace","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2018.08.012_bb0640","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.3892\/ol.2017.6325","article-title":"Repurposing itraconazole as an anticancer agent","volume":"14","author":"Tsubamoto","year":"2017","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.addr.2018.08.012_bb0645","first-page":"3521","article-title":"Itraconazole modulates hedgehog, WNT\/beta-catenin, as well as akt signalling, and inhibits proliferation of cervical cancer cells","volume":"37","author":"Ueda","year":"2017","journal-title":"Anticancer Res."},{"key":"10.1016\/j.addr.2018.08.012_bb0650","doi-asserted-by":"crossref","first-page":"28510","DOI":"10.18632\/oncotarget.15324","article-title":"Itraconazole exerts its anti-melanoma effect by suppressing Hedgehog, Wnt, and PI3K\/mTOR signaling pathways","volume":"8","author":"Liang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.addr.2018.08.012_bb0655","first-page":"27","article-title":"Itraconazole can inhibit malignant pleural effusion by suppressing lymphangiogenesis in mice","volume":"4","author":"Wang","year":"2015","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.addr.2018.08.012_bb0660","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.4161\/auto.28912","article-title":"Itraconazole suppresses the growth of glioblastoma through induction of autophagy","volume":"10","author":"Liu","year":"2014","journal-title":"Autophagy"},{"key":"10.1016\/j.addr.2018.08.012_bb0665","doi-asserted-by":"crossref","first-page":"6764","DOI":"10.1158\/0008-5472.CAN-11-0691","article-title":"Itraconazole inhibits angiogenesis and tumor growth in non\u2013small cell lung cancer","volume":"71","author":"Aftab","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2018.08.012_bb0670","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/JTO.0b013e31828c3950","article-title":"Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer","volume":"8","author":"Rudin","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.addr.2018.08.012_bb0675","doi-asserted-by":"crossref","first-page":"E7276","DOI":"10.1073\/pnas.1512867112","article-title":"Antifungal drug itraconazole targets VDAC1 to modulate the AMPK\/mTOR signaling axis in endothelial cells","volume":"112","author":"Head","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2018.08.012_bb0680","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.powtec.2012.01.045","article-title":"Development of chitosan-based nanoparticles for pulmonary delivery of itraconazole as dry powder formulation","volume":"222","author":"Jafarinejad","year":"2012","journal-title":"Powder Technol."},{"key":"10.1016\/j.addr.2018.08.012_bb0685","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ijpharm.2017.09.024","article-title":"Development of fine solid-crystal suspension with enhanced solubility, stability, and aerosolization performance for dry powder inhalation","volume":"533","author":"Lin","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2018.08.012_bb0690","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijpharm.2012.03.002","article-title":"Solid dispersions of itraconazole for inhalation with enhanced dissolution, solubility and dispersion properties","volume":"428","author":"Duret","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2018.08.012_bb0695","doi-asserted-by":"crossref","first-page":"57","DOI":"10.15171\/apb.2016.009","article-title":"Aggregated nanotransfersomal dry powder inhalation of itraconazole for pulmonary drug delivery","volume":"6","author":"Hassanpour Aghdam","year":"2016","journal-title":"Adv. Pharm. Bull."},{"key":"10.1016\/j.addr.2018.08.012_bb0700","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3332\/ecancer.2015.513","article-title":"Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agent","volume":"9","author":"Van Nuffel","year":"2015","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.addr.2018.08.012_bb0705","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000075069","article-title":"Suppression of postoperative systemic inflammatory response syndrome with clarithromycin following lung cancer surgery","volume":"36","author":"Hirata","year":"2004","journal-title":"Eur. Surg. Res."},{"key":"10.1016\/j.addr.2018.08.012_bb0710","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.intimp.2004.05.011","article-title":"Clarithromycin and azithromycin induce apoptosis of activated lymphocytes via down-regulation of Bcl-xL","volume":"4","author":"Mizunoe","year":"2004","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.addr.2018.08.012_bb0715","first-page":"815","article-title":"Clarithromycin attenuates autophagy in myeloma cells","volume":"37","author":"Nakamura","year":"2010","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.addr.2018.08.012_bb0720","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1038\/leusup.2012.25","article-title":"Inhibition of autophagy with clarithromycin: a new strategy to enhance sensitivity of CML stem cells to tyrosine kinase inhibitors","volume":"1","author":"Carella","year":"2012","journal-title":"Leuk. Suppl."},{"key":"10.1016\/j.addr.2018.08.012_bb0725","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s004330050068","article-title":"Clarithromycin is a potent inhibitor of tumor-induced angiogenesis","volume":"197","author":"Yatsunami","year":"1997","journal-title":"Res. Exp. Med."},{"key":"10.1016\/j.addr.2018.08.012_bb0730","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000007256","article-title":"Adjuvant effect of clarithromycin on chemotherapy for murine lung cancer","volume":"46","author":"Hamada","year":"2000","journal-title":"Chemotherapy"},{"key":"10.1016\/j.addr.2018.08.012_bb0735","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1023\/A:1006605725619","article-title":"Antiangiogenic and antitumor effects of 14-membered ring macrolides on mouse B16 melanoma cells","volume":"17","author":"Yatsunami","year":"1999","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.addr.2018.08.012_bb0740","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ijpharm.2017.03.079","article-title":"Clarithromycin and N-acetylcysteine co-spray-dried powders for pulmonary drug delivery: a focus on drug solubility","volume":"533","author":"Manniello","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2018.08.012_bb0745","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ijpharm.2013.06.047","article-title":"Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols","volume":"455","author":"Park","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2018.08.012_bb0750","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.powtec.2016.09.053","article-title":"Inhalable clarithromycin liposomal dry powders using ultrasonic spray freeze drying","volume":"305","author":"Ye","year":"2017","journal-title":"Powder Technol."},{"key":"10.1016\/j.addr.2018.08.012_bb0755","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/jphp.12190","article-title":"The formulation, chemical and physical characterisation of clarithromycin-based macrolide solution pressurised metered dose inhaler","volume":"66","author":"Saadat","year":"2014","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.addr.2018.08.012_bb0760","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1007\/s11095-014-1605-y","article-title":"Immunomodulatory effects of a low-dose clarithromycin-based macrolide solution pressurised metered dose inhaler","volume":"32","author":"Haghi","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2018.08.012_bb0765","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.powtec.2013.02.025","article-title":"Development of a nano\u2013micro carrier system for sustained pulmonary delivery of clarithromycin","volume":"239","author":"Moghaddam","year":"2013","journal-title":"Powder Technol."},{"key":"10.1016\/j.addr.2018.08.012_bb0770","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.phrs.2014.06.013","article-title":"Novel prospects of statins as therapeutic agents in cancer","volume":"88","author":"Pisanti","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.addr.2018.08.012_bb0775","doi-asserted-by":"crossref","first-page":"15051","DOI":"10.1073\/pnas.0910258107","article-title":"Dysregulation of the mevalonate pathway promotes transformation","volume":"107","author":"Clendening","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.addr.2018.08.012_bb0780","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1159\/000082918","article-title":"Higher farnesyl diphosphate synthase activity in human colorectal cancer inhibition of cellular apoptosis","volume":"67","author":"Notarnicola","year":"2004","journal-title":"Oncology"},{"key":"10.1016\/j.addr.2018.08.012_bb0785","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s10637-010-9450-2","article-title":"Apoptotic induction by simvastatin in human lung cancer A549 cells via Akt signaling dependent down-regulation of survivin","volume":"29","author":"Hwang","year":"2011","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.addr.2018.08.012_bb0790","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1161\/hc0602.103393","article-title":"Statins have biphasic effects on angiogenesis","volume":"105","author":"Weis","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2018.08.012_bb0795","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3727\/096504013X13657689382897","article-title":"Simvastatin inhibits proliferation and induces apoptosis in human lung cancer cells","volume":"20","author":"Yu","year":"2012","journal-title":"Oncol. Res."},{"key":"10.1016\/j.addr.2018.08.012_bb0800","doi-asserted-by":"crossref","first-page":"4819","DOI":"10.1007\/s13277-015-3134-7","article-title":"Simvastatin downregulates expression of TGF-\u03b2RII and inhibits proliferation of A549 cells via ERK","volume":"36","author":"Shang","year":"2015","journal-title":"Tumor Biol."},{"key":"10.1016\/j.addr.2018.08.012_bb0805","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/2050-6511-15-67","article-title":"Effects of simvastatin on cell viability and proinflammatory pathways in lung adenocarcinoma cells exposed to hydrogen peroxide","volume":"15","author":"Gallelli","year":"2014","journal-title":"BMC Pharmacol. Toxicol."},{"key":"10.1016\/j.addr.2018.08.012_bb0810","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1517\/17425247.2015.963054","article-title":"Dry powder formulation of simvastatin","volume":"12","author":"Tulbah","year":"2015","journal-title":"Expert. Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2018.08.012_bb0815","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1208\/s12249-014-0127-6","article-title":"Novel simvastatin inhalation formulation and characterisation","volume":"15","author":"Tulbah","year":"2014","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.addr.2018.08.012_bb0820","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s11095-015-1766-3","article-title":"Biological effects of simvastatin formulated as pMDI on pulmonary epithelial cells","volume":"33","author":"Tulbah","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2018.08.012_bb0825","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ijpharm.2010.03.058","article-title":"Pulmonary delivery of cisplatin-hyaluronan conjugates via endotracheal instillation for the treatment of lung cancer","volume":"392","author":"Xie","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2018.08.012_bb0830","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ijpharm.2013.06.011","article-title":"Establishing the optimal nebulization system for paclitaxel, docetaxel, cisplatin, carboplatin and gemcitabine: back to drawing the residual cup","volume":"453","author":"Zarogoulidis","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2018.08.012_bb0835","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ijpharm.2016.10.019","article-title":"Development of controlled-release cisplatin dry powders for inhalation against lung cancers","volume":"515","author":"Levet","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2018.08.012_bb0840","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.ijpharm.2016.12.037","article-title":"Platinum pharmacokinetics in mice following inhalation of cisplatin dry powders with different release and lung retention properties","volume":"517","author":"Levet","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2018.08.012_bb0845","doi-asserted-by":"crossref","first-page":"521","DOI":"10.4103\/0250-474X.110584","article-title":"Development of chitosan-based dry powder inhalation system of cisplatin for lung cancer","volume":"74","author":"Singh","year":"2012","journal-title":"Indian J. Pharm. Sci."},{"key":"10.1016\/j.addr.2018.08.012_bb0850","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1007\/s11095-016-1976-3","article-title":"Intratracheal administration of hyaluronan-cisplatin conjugate nanoparticles significantly attenuates lung cancer growth in mice","volume":"33","author":"Ishiguro","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2018.08.012_bb0855","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1016\/j.biomaterials.2008.03.033","article-title":"Targeting efficiency and biodistribution of biotinylated-EGF-conjugated gelatin nanoparticles administered via aerosol delivery in nude mice with lung cancer","volume":"29","author":"Tseng","year":"2008","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2018.08.012_bb0860","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1016\/j.biomaterials.2009.03.010","article-title":"The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation","volume":"30","author":"Tseng","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2018.08.012_bb0865","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/pbc.24438","article-title":"Inhaled lipid cisplatin (ILC) in the treatment of patients with relapsed\/progressive osteosarcoma metastatic to the lung","volume":"60","author":"Chou","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.addr.2018.08.012_bb0870","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/00000421-198502000-00052","article-title":"Cisplatin nephrotoxicity. Correlation with plasma platinum concentrations","volume":"8","author":"Kelsen","year":"1985","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.addr.2018.08.012_bb0875","doi-asserted-by":"crossref","first-page":"344","DOI":"10.7150\/jca.9021","article-title":"Enhancement of aerosol cisplatin chemotherapy with gene therapy expressing ABC10 protein in respiratory system","volume":"5","author":"Hohenforst-Schmidt","year":"2014","journal-title":"J. Cancer"},{"key":"10.1016\/j.addr.2018.08.012_bb0880","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1158\/1078-0432.CCR-06-1480","article-title":"Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung","volume":"13","author":"Wittgen","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2018.08.012_bb0885","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3109\/02652048.2014.944949","article-title":"Inhalable, large porous PLGA microparticles loaded with paclitaxel: preparation, in vitro and in vivo characterization","volume":"32","author":"Alipour","year":"2015","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.addr.2018.08.012_bb0890","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.colsurfb.2010.07.050","article-title":"Preparation and characterization of biodegradable paclitaxel loaded alginate microparticles for pulmonary delivery","volume":"81","author":"Alipour","year":"2010","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.addr.2018.08.012_bb0895","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s002800000230","article-title":"Improved respiratory delivery of the anticancer drugs, camptothecin and paclitaxel, with 5% CO2-enriched air: pharmacokinetic studies","volume":"47","author":"Koshkina","year":"2001","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.addr.2018.08.012_bb0900","first-page":"3258","article-title":"Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model","volume":"7","author":"Koshkina","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2018.08.012_bb0905","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jconrel.2016.08.008","article-title":"PEGylation of paclitaxel largely improves its safety and anti-tumor efficacy following pulmonary delivery in a mouse model of lung carcinoma","volume":"239","author":"Luo","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2018.08.012_bb0910","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ejpb.2011.04.017","article-title":"Paclitaxel loaded PEG(5000)-DSPE micelles as pulmonary delivery platform: formulation characterization, tissue distribution, plasma pharmacokinetics, and toxicological evaluation","volume":"79","author":"Gill","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2018.08.012_bb0915","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.ejps.2013.05.012","article-title":"Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer","volume":"49","author":"Meenach","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2018.08.012_bb0920","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.nano.2011.12.007","article-title":"Preclinical evaluation of a pulmonary delivered paclitaxel-loaded lipid nanocarrier antitumor effect","volume":"8","author":"Videira","year":"2012","journal-title":"Nanomedicine"},{"key":"10.1016\/j.addr.2018.08.012_bb0925","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ejpb.2009.06.013","article-title":"Lipid nanocapsules: ready-to-use nanovectors for the aerosol delivery of paclitaxel","volume":"73","author":"Hureaux","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2018.08.012_bb0930","doi-asserted-by":"crossref","first-page":"7085","DOI":"10.1038\/srep07085","article-title":"Endogenous lung surfactant inspired pH responsive nanovesicle aerosols: pulmonary compatible and site-specific drug delivery in lung metastases","volume":"4","author":"Joshi","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2018.08.012_bb0935","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jddst.2016.04.001","article-title":"Tumor distribution and anti-tumor effect of doxorubicin following intrapulmonary administration to mice with metastatic lung tumor","volume":"33","author":"Kanehira","year":"2016","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.addr.2018.08.012_bb0940","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1089\/jamp.2011-0966","article-title":"Characterization and application of a nose-only exposure chamber for inhalation delivery of liposomal drugs and nucleic acids to mice","volume":"26","author":"Mainelis","year":"2013","journal-title":"J. Aerosol. Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2018.08.012_bb0945","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2217\/17435889.3.6.761","article-title":"Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer","volume":"3","author":"Saad","year":"2008","journal-title":"Nanomedicine (London)"},{"key":"10.1016\/j.addr.2018.08.012_bb0950","doi-asserted-by":"crossref","first-page":"900","DOI":"10.3109\/1061186X.2011.622404","article-title":"Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA","volume":"19","author":"Taratula","year":"2011","journal-title":"J. Drug Target."},{"key":"10.1016\/j.addr.2018.08.012_bb0955","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jconrel.2013.04.018","article-title":"Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA","volume":"171","author":"Taratula","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2018.08.012_bb0960","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ejps.2006.07.004","article-title":"In vitro assessment of transferrin-conjugated liposomes as drug delivery systems for inhalation therapy of lung cancer","volume":"29","author":"Anabousi","year":"2006","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2018.08.012_bb0965","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijpharm.2016.11.039","article-title":"Fabrication of liposomal doxorubicin exhibiting ultrasensitivity against phospholipase A2 for efficient pulmonary drug delivery to lung cancers","volume":"517","author":"Tagami","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2018.08.012_bb0970","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3109\/10837450.2013.852576","article-title":"Feasibility of haloperidol-anchored albumin nanoparticles loaded with doxorubicin as dry powder inhaler for pulmonary delivery","volume":"20","author":"Varshosaz","year":"2015","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.addr.2018.08.012_bb0975","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jconrel.2014.11.008","article-title":"Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer","volume":"197","author":"Choi","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2018.08.012_bb0980","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12951-014-0037-5","article-title":"Anticancer drug-loaded multifunctional nanoparticles to enhance the chemotherapeutic efficacy in lung cancer metastasis","volume":"12","author":"Long","year":"2014","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.addr.2018.08.012_bb0985","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.1016\/j.biomaterials.2012.04.018","article-title":"Doxorubicin-loaded highly porous large PLGA microparticles as a sustained- release inhalation system for the treatment of metastatic lung cancer","volume":"33","author":"Kim","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2018.08.012_bb0990","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.ejpb.2014.09.012","article-title":"Synergistic co-delivery of doxorubicin and paclitaxel by porous PLGA microspheres for pulmonary inhalation treatment","volume":"88","author":"Feng","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2018.08.012_bb0995","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1021\/acs.molpharmaceut.5b00876","article-title":"Poly(amidoamine) dendrimer-doxorubicin conjugates: in vitro characteristics and pseudosolution formulation in pressurized metered-dose inhalers","volume":"13","author":"Zhong","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2018.08.012_bb1000","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1021\/acs.molpharmaceut.6b00126","article-title":"Conjugation to poly(amidoamine) dendrimers and pulmonary delivery reduce cardiac accumulation and enhance antitumor activity of doxorubicin in lung metastasis","volume":"13","author":"Zhong","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2018.08.012_bb1005","doi-asserted-by":"crossref","first-page":"12941","DOI":"10.1021\/la502144z","article-title":"Biodegradable Janus nanoparticles for local pulmonary delivery of hydrophilic and hydrophobic molecules to the lungs","volume":"30","author":"Garbuzenko","year":"2014","journal-title":"Langmuir"},{"key":"10.1016\/j.addr.2018.08.012_bb1010","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ijbiomac.2017.01.109","article-title":"Inhalable bioresponsive chitosan microspheres of doxorubicin and soluble curcumin augmented drug delivery in lung cancer cells","volume":"98","author":"Jyoti","year":"2017","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.addr.2018.08.012_bb1015","doi-asserted-by":"crossref","first-page":"6444","DOI":"10.1016\/j.biomaterials.2013.05.018","article-title":"Doxorubicin-loaded porous PLGA microparticles with surface attached TRAIL for the inhalation treatment of metastatic lung cancer","volume":"34","author":"Kim","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2018.08.012_bb1020","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s11671-017-1826-1","article-title":"Effect of paclitaxel-mesoporous silica nanoparticles with a core-shell structure on the human lung cancer cell line A549","volume":"12","author":"Wang","year":"2017","journal-title":"Nanoscale Res. Lett."},{"key":"10.1016\/j.addr.2018.08.012_bb1025","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ijpharm.2016.01.073","article-title":"Development and evaluation of well-tolerated and tumor-penetrating polymeric micelle-based dry powders for inhaled anti-cancer chemotherapy","volume":"501","author":"Rosiere","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2018.08.012_bb1030","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1089\/jamp.2015.1286","article-title":"Development of optimized, inhalable, gemcitabine-loaded gelatin nanocarriers for lung cancer","volume":"30","author":"Youngren-Ortiz","year":"2017","journal-title":"J. Aerosol. Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2018.08.012_bb1035","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1139\/Y08-039","article-title":"Pulmonary gemcitabine delivery for treating lung cancer: pharmacokinetics and acute lung injury aspects in animals","volume":"86","author":"Min","year":"2008","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.addr.2018.08.012_bb1040","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00280-005-0146-9","article-title":"Gemcitabine aerosol: in vitro antitumor activity and deposition imaging for preclinical safety assessment in baboons","volume":"58","author":"Gagnadoux","year":"2006","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.addr.2018.08.012_bb1045","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jconrel.2014.03.012","article-title":"Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy","volume":"183","author":"Kaminskas","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2018.08.012_bb1050","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.cclet.2016.12.013","article-title":"Anti-tumor effects of combined doxorubicin and siRNA for pulmonary delivery","volume":"28","author":"Xu","year":"2017","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.addr.2018.08.012_bb1055","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1039\/C6BM00601A","article-title":"The suppression of metastatic lung cancer by pulmonary administration of polymer nanoparticles for co-delivery of doxorubicin and Survivin siRNA","volume":"4","author":"Xu","year":"2016","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.addr.2018.08.012_bb1060","doi-asserted-by":"crossref","first-page":"103380","DOI":"10.1039\/C5RA21934E","article-title":"A pH sensitive co-delivery system of siRNA and doxorubicin for pulmonary administration to B16F10 metastatic lung cancer","volume":"5","author":"Xu","year":"2015","journal-title":"RSC Adv."},{"key":"10.1016\/j.addr.2018.08.012_bb1065","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1158\/1078-0432.CCR-06-1096","article-title":"Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs","volume":"13","author":"Otterson","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2018.08.012_bb1070","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1158\/1078-0432.CCR-09-3015","article-title":"Phase I\/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non-small cell lung cancer","volume":"16","author":"Otterson","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2018.08.012_bb1075","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/s41598-017-00957-4","article-title":"Pulmonary delivery of triptolide-loaded liposomes decorated with anti-carbonic anhydrase IX antibody for lung cancer therapy","volume":"7","author":"Lin","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2018.08.012_bb1080","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1158\/1940-6207.CAPR-14-0142","article-title":"Enhanced antitumor activity of 3-bromopyruvate in combination with rapamycin in vivo and in vitro","volume":"8","author":"Zhang","year":"2015","journal-title":"Cancer Prev. Res. (Phila.)"},{"key":"10.1016\/j.addr.2018.08.012_bb1085","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1158\/1940-6207.CAPR-11-0338","article-title":"Aerosolized 3-bromopyruvate inhibits lung tumorigenesis without causing liver toxicity","volume":"5","author":"Zhang","year":"2012","journal-title":"Cancer Prev. Res. (Phila.)"},{"key":"10.1016\/j.addr.2018.08.012_bb1090","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00280-004-0817-y","article-title":"Novel vitamin E analogue and 9-nitro-camptothecin administered as liposome aerosols decrease syngeneic mouse mammary tumor burden and inhibit metastasis","volume":"54","author":"Lawson","year":"2004","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.addr.2018.08.012_bb1095","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1749-6632.2000.tb07033.x","article-title":"9-Nitrocamptothecin liposome aerosol treatment of human cancer subcutaneous xenografts and pulmonary cancer metastases in mice","volume":"922","author":"Knight","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.addr.2018.08.012_bb1100","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3109\/1061186X.2013.878944","article-title":"Inhalable microspheres embedding chitosan-coated PLGA nanoparticles for 2-methoxyestradiol","volume":"22","author":"Guo","year":"2014","journal-title":"J. Drug Target."},{"key":"10.1016\/j.addr.2018.08.012_bb1105","first-page":"3129","article-title":"Antitumor effect of inhalatory lipopolysaccharide and synergetic effect in combination with cyclophosphamide","volume":"30","author":"Hirota","year":"2010","journal-title":"Anticancer Res."},{"key":"10.1016\/j.addr.2018.08.012_bb1110","first-page":"585","article-title":"Preparation and characterization of solid lipid nanoparticles loaded with epirubicin for pulmonary delivery","volume":"65","author":"Hu","year":"2010","journal-title":"Pharmazie"},{"key":"10.1016\/j.addr.2018.08.012_bb1115","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/ijc.21011","article-title":"Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases","volume":"116","author":"Koshkina","year":"2005","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.addr.2018.08.012_bb1120","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1002\/cncr.10602","article-title":"Phase II trial of gemcitabine in advanced sarcomas","volume":"94","author":"Okuno","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.addr.2018.08.012_bb1125","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1089\/jamp.2009.0812","article-title":"Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas\/FasL pathway and rationale for the use of gemcitabine","volume":"23","author":"Gordon","year":"2010","journal-title":"J. Aerosol. Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2018.08.012_bb1130","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1158\/1078-0432.CCR-07-0313","article-title":"Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine","volume":"13","author":"Gordon","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2018.08.012_bb1135","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1089\/jamp.2009.0773","article-title":"Aerosol gemcitabine: preclinical safety and in vivo antitumor activity in osteosarcoma-bearing dogs","volume":"23","author":"Rodriguez","year":"2010","journal-title":"J. Aerosol. Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2018.08.012_bb1140","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1089\/jam.2005.18.198","article-title":"Safety of pulmonary administration of gemcitabine in rats","volume":"18","author":"Gagnadoux","year":"2005","journal-title":"J. Aerosol. Med."},{"key":"10.1016\/j.addr.2018.08.012_bb1145","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1183\/09031936.05.00017305","article-title":"Aerosol delivery of chemotherapy in an orthotopic model of lung cancer","volume":"26","author":"Gagnadoux","year":"2005","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.addr.2018.08.012_bb1150","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1089\/jamp.2010.0822","article-title":"Targeted combined aerosol chemotherapy in dogs and radiologic toxicity grading","volume":"24","author":"Selting","year":"2011","journal-title":"J. Aerosol. Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2018.08.012_bb1155","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1089\/jamp.2010.0872","article-title":"Aerosolized gemcitabine in patients with carcinoma of the lung: feasibility and safety study","volume":"24","author":"Lemarie","year":"2011","journal-title":"J. Aerosol. Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2018.08.012_bb1160","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.ijbiomac.2017.05.127","article-title":"Chitosan stabilized camptothecin nanoemulsions: development, evaluation and biodistribution in preclinical breast cancer animal mode","volume":"104 (","author":"Natesan","year":"2017","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.addr.2018.08.012_bb1165","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1080\/10717544.2017.1303856","article-title":"Enhanced cytotoxic effect of camptothecin nanosponges in anaplastic thyroid cancer cells in vitro and in vivo on orthotopic xenograft tumors","volume":"24","author":"Gigliotti","year":"2017","journal-title":"Drug Deliv."},{"issue":"2016","key":"10.1016\/j.addr.2018.08.012_bb1170","doi-asserted-by":"crossref","first-page":"9128102","DOI":"10.1155\/2016\/9128102","article-title":"An acetamide derivative as a camptothecin sensitizer for human non-small-cell lung cancer cells through increased oxidative stress and JNK activation","author":"Chou","year":"2016","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.addr.2018.08.012_bb1175","first-page":"941","article-title":"The antitumor and antimetastatic effects of N-trimethyl chitosan-encapsulated camptothecin on ovarian cancer with minimal side effects","volume":"24","author":"Zhou","year":"2010","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.addr.2018.08.012_bb1180","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s002800050965","article-title":"Anticancer effect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice","volume":"44","author":"Knight","year":"1999","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.addr.2018.08.012_bb1185","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s002800050966","article-title":"Distribution of camptothecin after delivery as a liposome aerosol or following intramuscular injection in mice","volume":"44","author":"Koshkina","year":"1999","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.addr.2018.08.012_bb1190","first-page":"2876","article-title":"9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice","volume":"6","author":"Koshkina","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2018.08.012_bb1195","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.pupt.2007.04.002","article-title":"Biodistribution in mice and severity of damage in rat lungs following pulmonary delivery of 9-nitrocamptothecin liposomes","volume":"21","author":"Zhang","year":"2008","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2018.08.012_bb1200","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1749-6632.2000.tb07063.x","article-title":"Feasibility, phase I, and pharmacological study of aerosolized liposomal 9-nitro-20(S)-camptothecin in patients with advanced malignancies in the lungs","volume":"922","author":"Verschraegen","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.addr.2018.08.012_bb1205","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s11095-010-0329-x","article-title":"Temozolomide-based dry powder formulations for lung tumor-related inhalation treatment","volume":"28","author":"Wauthoz","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2018.08.012_bb1210","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3892\/ijo.2015.3092","article-title":"New dry powders for inhalation containing temozolomide-based nanomicelles for improved lung cancer therapy","volume":"47","author":"Rosiere","year":"2015","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.addr.2018.08.012_bb1215","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ejps.2010.01.010","article-title":"In vivo assessment of temozolomide local delivery for lung cancer inhalation therapy","volume":"39","author":"Wauthoz","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2018.08.012_bb1220","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1080\/10717544.2016.1247924","article-title":"Antitumor activity of intratracheal inhalation of temozolomide (TMZ) loaded into gold nanoparticles and\/or liposomes against urethane-induced lung cancer in BALB\/c mice","volume":"24","author":"Hamzawy","year":"2017","journal-title":"Drug Deliv."},{"key":"10.1016\/j.addr.2018.08.012_bb1225","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/jps.20590","article-title":"Development of a respirable, sustained release microcarrier for 5-fluorouracil II: in vitro and in vivo optimization of lipid coated nanoparticles","volume":"95","author":"Hitzman","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2018.08.012_bb1230","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1002\/jps.20607","article-title":"Pharmacokinetics of 5-fluorouracil in the hamster following inhalation delivery of lipid-coated nanoparticles","volume":"95","author":"Hitzman","year":"2006","journal-title":"J. Pharm. Sci."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X18302102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X18302102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T04:41:22Z","timestamp":1759207282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X18302102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":246,"alternative-id":["S0169409X18302102"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2018.08.012","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The potential to treat lung cancer via inhalation of repurposed drugs","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2018.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}